Kirsten is an economist, a consultant, and a Senior Policy Advisor to DLA Piper. She is a visiting scholar with the American Enterprise Institute and an Aspen Institute Health Fellow.
Kirsten was on the leadership team of Pfizer Inc’s $30 billion global innovative pharmaceutical business, where she led Strategy and Business Evaluation. Kirsten led multiple global reorganizations, and developed corporate strategy for emerging markets, digital technology and for a more patient-centric approach. She oversaw business development evaluation for rare disease, oncology, inflammation & immunology, and primary care. Kirsten also led Pfizer’s Global Policy team. She is a published author including on the impact of Medicaid preferred drug lists on health disparities and adherence to medicines.
Kirsten is a board member for Ramapo for Children, she worked in Ethiopia with the International Trachoma initiative and climbed Mt. Kilimanjaro to raise $1.6 million for the Fred Hutchinson Cancer Center. She is the founder and Secretary of the PTEC."
Kirsten was on the leadership team of Pfizer Inc’s $30 billion global innovative pharmaceutical business, where she led Strategy and Business Evaluation. Kirsten led multiple global reorganizations, and developed corporate strategy for emerging markets, digital technology and for a more patient-centric approach. She oversaw business development evaluation for rare disease, oncology, inflammation & immunology, and primary care. Kirsten also led Pfizer’s Global Policy team. She is a published author including on the impact of Medicaid preferred drug lists on health disparities and adherence to medicines.
Kirsten is a board member for Ramapo for Children, she worked in Ethiopia with the International Trachoma initiative and climbed Mt. Kilimanjaro to raise $1.6 million for the Fred Hutchinson Cancer Center. She is the founder and Secretary of the PTEC."
Speaking In
11:00 AM - 12:00 PM
Wednesday, June 7
